AOD 9604 dosing protocol explained: typical research doses, timing, frequency, and what studies show about fat loss, safety, and side effects.
The most commonly referenced AOD 9604 dosing protocol is 250 to 500 micrograms injected subcutaneously once per day, usually in the morning on an empty stomach. Many user guides settle on 300 mcg daily, while early human trials tested different amounts. No universal or FDA-approved dose exists, because AOD-9604 is not approved for human use in the United States.
What Is AOD 9604?
AOD-9604 is a synthetic peptide built from a small fragment of human growth hormone. It contains the final 16 amino acids of the growth hormone molecule (residues 176–191), a region researchers once believed was responsible for fat breakdown.
The goal was to keep the fat-metabolizing effect of growth hormone while avoiding its effects on blood sugar and tissue growth. AOD-9604 was studied in the 1990s and 2000s as an anti-obesity drug, but it never received FDA approval. Today it is sold as a research chemical rather than a medication.
Typical AOD 9604 Dosing Protocol
Because no official aod 9604 dosage protocol exists, most numbers you see online come from early trials, animal studies, or user reports. The table below summarizes the ranges that appear most often.
| Parameter | Commonly cited range | Notes |
|---|---|---|
| Dose per injection | 250–500 mcg | 300 mcg is the most frequently repeated number |
| Frequency | Once daily | A few users split the dose into two shots |
| Timing | Morning, fasted | Often 20–30 minutes before eating |
| Route | Subcutaneous | Abdomen, thigh, or upper arm |
| Cycle length | 8–12 weeks | Usually followed by a break |
| Storage | Refrigerated, 2–8°C | Protect from light and repeated warming |
These figures are not standardized. Two people following the same written protocol may use different doses, injection sites, and cycle lengths.
Should You Split the Dose?
Most protocols use a single daily injection. Splitting the dose into two smaller shots is sometimes suggested, but there is no published evidence that it improves results. A once-daily schedule is easier to track and matches the format used in most research.
How Long Do People Run It?
Typical cycles run 8 to 12 weeks, followed by a break. Continuous long-term use has not been studied in humans, and no safety data support running it for months at a time.
Timing and Injection Basics
AOD-9604 is usually injected into the subcutaneous fat of the abdomen, thigh, or upper arm. Rotating sites helps reduce irritation and bruising.
- Morning, fasted: Most protocols place the injection before breakfast.
- Same time daily: Consistency makes it easier to track effects and side effects.
- Clean technique: Use alcohol swabs and never reuse needles.
- Cold storage: Keep the vial refrigerated and avoid shaking it.
Some guides describe an aod 9604 dosing schedule female users reportedly follow, but there is no evidence that women need a different dose than men. Body weight and individual response matter more than sex.
How AOD 9604 Compares With Other Fat-Loss Compounds
AOD-9604 is often weighed against other peptides and medications that affect fat and metabolism. The table below outlines where they differ.
| Compound | Class | Typical dose | FDA status | Reported effect |
|---|---|---|---|---|
| AOD-9604 | hGH fragment 176–191 | 250–500 mcg daily (research) | Not approved | Modest, inconsistent fat loss in trials |
| Tesamorelin | GHRH analog | 2 mg daily (clinical) | Approved for HIV-related lipodystrophy | Reduces visceral fat |
| MOTS-c | Mitochondrial-derived peptide | 5–10 mg weekly (research) | Not approved | Studied for insulin sensitivity and metabolism |
| Tirzepatide | GIP/GLP-1 dual agonist | 2.5–15 mg weekly (clinical) | Approved for type 2 diabetes and weight management | Large average weight loss |
The comparison of aod 9604 vs tesamorelin matters because tesamorelin is the only FDA-approved drug in this group, and its effect on visceral fat is supported by clinical trials. AOD-9604 has far weaker evidence behind it.
Researchers comparing aod 9604 vs mots-c are looking at two very different mechanisms: a growth hormone fragment versus a mitochondrial peptide. Neither one is approved for weight loss.
Stacking AOD-9604 with tirzepatide is sometimes discussed online, but no clinical data cover the combination. Tirzepatide already produces substantial weight loss on its own, so adding an unapproved peptide increases risk without proven benefit.
What the Evidence Says
Independent aod 9604 reviews are mixed. Early human trials reported only modest weight loss, and some results were not clearly different from placebo.
AOD-9604 has been studied far more in animals than in people. The human studies were short, used different doses, and did not produce the dramatic fat loss seen with approved obesity medications.
AOD-9604 is not FDA-approved for human use in the United States, and it should not be treated as a proven weight-loss treatment.
Safety, Side Effects, and Legal Status
AOD-9604 is sold as a research chemical, which means it is not manufactured under pharmaceutical standards. Purity and actual peptide content can vary between vendors, and independent testing is rare.
Reported side effects in studies were generally mild and included injection-site reactions, headache, and nausea. Long-term human safety data remain limited, and interactions with prescription drugs are largely unknown.
- AOD-9604 is not approved by the FDA for weight loss or any other human use.
- Research-grade peptides are not subject to the same quality controls as prescription drugs.
- Little is known about how AOD-9604 interacts with GLP-1 medications or other prescriptions.
- Pregnant or breastfeeding women, and people with hormone-sensitive conditions, should avoid it.
Anyone considering AOD-9604 should talk with a healthcare professional and should not use it as a substitute for proven treatments.
Practical Summary
If you are mapping out a protocol, most references point to 250–500 mcg once daily, injected subcutaneously in the morning while fasted, for 8–12 weeks. That is a community standard, not a medical one.
The honest takeaway: AOD-9604 has weak evidence, no FDA approval, and no confirmed dosing standard. Anyone focused on fat loss should first discuss proven options with a clinician.
Frequently Asked Questions
How much AOD 9604 is typically used per day?
Most research and community protocols cite 250 to 500 micrograms injected subcutaneously once daily, with 300 mcg being the most commonly repeated number. No FDA-approved human dose exists, and early trials used varying amounts, so there is no standard protocol. Any decision about use should involve a healthcare professional.
Does AOD 9604 actually cause fat loss?
Human trials of AOD-9604 reported only modest and inconsistent weight loss, and the drug was never approved for obesity treatment. User reviews are mixed, with some people reporting mild changes and others seeing no difference. Approved options such as GLP-1 medications have much stronger evidence behind them.
When and where should AOD 9604 be injected?
Most protocols call for a subcutaneous injection in the morning on an empty stomach, using the abdomen, thigh, or upper arm. Injection sites should be rotated, and the vial should stay refrigerated. A healthcare professional should be consulted before starting any peptide protocol.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.